Unpacking the Momentum Driving Agilent Technologies Stock.

Agilent Technologies shares rose 1.6% this afternoon to a price of $147.48. The stock is still trading within range of its average target price of $145.5, and over the last 52 weeks, it has recorded a 9.6% performance. Analysts have given the Large-Cap Biotechnology stock target prices ranging from $125.0 to $165.0 dollars per share, with an average rating of buy.

Agilent Technologies's short interest — meaning the percentage of the share float that is being shorted — is lower than average at 1.1%. The stock's short ratio is 1.74. The company's insiders own 0.28% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.

Another number to watch is the company's rate of institutional share ownership, which now stands at 91.7%. In conclusion, we believe there is mixed market sentiment regarding Agilent Technologies.

Institutions Invested in Agilent Technologies

Date Reported Holder Percentage Shares Value
2023-12-31 Blackrock Inc. 9% 27,257,939 $4,020,000,727
2023-12-31 Vanguard Group Inc 9% 25,279,117 $3,728,164,067
2023-12-31 Massachusetts Financial Services Co. 5% 13,246,489 $1,953,592,141
2023-12-31 State Street Corporation 4% 12,634,456 $1,863,329,516
2023-12-31 T. Rowe Price Investment Management, Inc. 3% 10,154,406 $1,497,571,753
2023-12-31 Wellington Management Group, LLP 3% 9,883,132 $1,457,564,265
2023-12-31 Price (T.Rowe) Associates Inc 3% 7,499,128 $1,105,971,365
2023-12-31 Geode Capital Management, LLC 2% 6,604,203 $973,987,830
2023-12-31 Pictet Asset Management Holding SA 2% 6,395,420 $943,196,514
2023-12-31 Morgan Stanley 2% 4,501,663 $663,905,240
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.